A Multiple Dose Study to Assess the Safety, Tolerability and PK of Risperidone Extended Release Capsules

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
Lyndra is developing an oral, extended release (ER) formulation of risperidone (LYN-005) presented in a capsule dosage form with the intent of reducing the frequency of dosing orally-administered medications to once weekly or less and thereby improving the management of schizophrenia. Study LYN-005-C-004 will evaluate the safety, tolerability, and pharmacokinetics (PK) of multiple dose administration of the ER formulation at two dose levels of LYN-005 relative to IR risperidone.
Epistemonikos ID: 8085d2b208deb010f804b63e2150065ba898e7a4
First added on: May 07, 2024